A 71-year-old man with well-controlled type 2 diabetes had a low white blood cell count that doctors could not explain. His doctor suspected his current diabetes medication, voglibose, might be the cause. Voglibose is a drug used to help control blood sugar levels. The patient had been taking it for a long time without other issues. To find the answer, his doctor replaced voglibose with a different drug called acarbose. This switch was a simple change in his daily routine. Two weeks after taking the new medication, his white blood cell count went up. It rose from a low range to a normal level. This improvement happened quickly after stopping the first drug. The medical team used a scoring system to check the link between the drug and the low count. This score suggested voglibose was the likely culprit. The patient tolerated the new drug well with no new problems. This case shows how checking medication lists can solve mysteries in patient care. Sometimes the answer lies in reviewing what a person takes every day. Doctors can use this approach to find hidden causes for unexplained health issues.
Switching diabetes drugs reversed low white blood cell counts in a 71-year-old man
Photo by CDC / Unsplash
What this means for you:
Switching from voglibose to acarbose raised white blood cell counts in a man with type 2 diabetes. More on Type 2 Diabetes
scFv-based biologics show potential for immunomodulation in type 1 and type 2 diabetes Review explores scFv biologics for Type 1 and Type 2 diabetes care
Frontiers · Jun 4, 2026
Insulin degludec/liraglutide ranks highest for HbA1c reduction with SUCRA value of 89.4% Comparing Combination Diabetes Drugs for Blood Sugar Control
· Jun 4, 2026
Metabolic subtypes identify Japanese adults with prediabetes at highest or lowest T2D risk Japanese adults with prediabetes benefit most from lifestyle changes in one specific metabolic group
· Jun 3, 2026
AI-driven cardiovascular risk prediction in type 2 diabetes shows promise but bias and lack of diversity limit clinical use New machine learning tools show promise but need better testing for diverse patients with diabetes
Frontiers · Jun 2, 2026